(19)
(11) EP 4 358 939 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.06.2025 Bulletin 2025/23

(45) Mention of the grant of the patent:
23.04.2025 Bulletin 2025/17

(21) Application number: 22735879.3

(22) Date of filing: 22.06.2022
(51) International Patent Classification (IPC): 
A61K 9/06(2006.01)
A61K 31/196(2006.01)
A61P 29/00(2006.01)
 A61K 47/24(2006.01)
A61P 19/02(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0014; A61K 9/06; A61K 31/196; A61K 47/24; A61P 29/00; A61P 19/02
(86) International application number:
PCT/EP2022/067018
(87) International publication number:
WO 2022/268882 (29.12.2022 Gazette 2022/52)

(54)

DICLOFENAC TOPICAL FORMULATION WITH A HIGH ABSORPTION RATE

TOPISCHE DICLOFENACFORMULIERUNG MIT HOHER ABSORPTIONSRATE

FORMULATION TOPIQUE DE DICLOFÉNAC À TAUX D'ABSORPTION ÉLEVÉ

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 25.06.2021 IT 202100016751

(43) Date of publication of application:
01.05.2024 Bulletin 2024/18

(60) Divisional application:
24158018.2 / 4364806

(73) Proprietor: IBSA INSTITUT BIOCHIMIQUE SA
6912 Lugano (CH)

(72) Inventors:
  • PUPPINI, Nadia
    6900 Lugano (CH)
  • NICOLINI, Valentina
    6900 Lugano (CH)
  • FOSSATI, Tiziano
    6900 Lugano (CH)

(74) Representative: M. Zardi & Co S.A. 
Via G. B. Pioda, 6
6900 Lugano
6900 Lugano (CH)


(56) References cited: : 
EP-A1- 0 372 527
US-A1- 2015 297 507
 CN-A- 105 395 544
   
  • FINI A ET AL: "Diclofenac/N-(2-hydroxyethyl)pyrrolidine: a new salt for an old drug", DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, BIOSCIENCE EDIPRINT INC, CH, vol. 19, no. 3, 1 January 1993 (1993-01-01), pages 81 - 88, XP009167977, ISSN: 0378-6501
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).